You are here: Industry Insights > HTD1801

News List

HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress ACN Newswire
April 25, 2025
HighTide Therapeutics announced that it will present at the EASL Congress 2025. The presentations include New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010).
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress PharmaSources
June 05, 2024
Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA ACN Newswire
April 16, 2025
HighTide Therapeutics Announces HTD1801 Meets the Primary Endpoints in Two Phase 3 Clinical Trials in Patients with Type 2 Diabetes Mellitus.
HighTide Therapeutics Announces Publication of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus Open ACN Newswire
March 05, 2025
HighTide Therapeutics announced that Phase 2 data of berberine ursodeoxycholate for treating T2DM was published in JAMA Network Open.
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) PharmaSources
January 12, 2023
HighTide Therapeutics Inc. announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
HighTide Therapeutics Receives Fast Track Designation for HTD1801 americanpharmaceuticalreview
September 29, 2018
HighTide Therapeutics announced the FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholangitis (PSC).